◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › V › VSTM

Verastem Inc (VSTM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-25

Verastem Inc (VSTM) operates in the BIOTECHNOLOGY industry and is headquartered in Needham, United States with about 102 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, VSTM reported $31M in revenue and ($209M) in net income.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.

Interactive charts & full statements → Open the VSTM valuation workbench →

VSTM Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Revenue	$88M	$31M	$10M	$0M	$3M	$2M	$89M	$17M	$27M	$0M	$0M	$0M	$0M	$0M	$0M	—	—
Gross Profit	$76M	$26M	$10M	$0M	$3M	$2M	$55M	$15M	$26M	($1M)	($1M)	($1M)	$0M	$0M	$0M	—	—
Gross Margin %	86.7%	82.9%	100.0%	—	100.0%	100.0%	61.9%	83.9%	97.8%	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($160M)	($170M)	($115M)	($92M)	($73M)	($61M)	($49M)	($132M)	($95M)	($68M)	($37M)	($58M)	($54M)	($41M)	($32M)	($14M)	($1M)
Operating Margin %	-182.6%	-550.3%	-1149.6%	—	-2809.6%	-2991.2%	-55.8%	-758.1%	-354.8%	—	—	—	—	—	—	—	—
Net Income	($203M)	($209M)	($131M)	($87M)	($74M)	($71M)	($68M)	($149M)	($72M)	($68M)	($36M)	($58M)	($53M)	($41M)	($32M)	($14M)	($1M)
Net Margin %	-231.6%	-677.6%	-1306.4%	—	-2843.3%	-3468.1%	-76.5%	-854.8%	-271.1%	—	—	—	—	—	—	—	—
EBITDA	($200M)	($208M)	($126M)	($83M)	($72M)	($61M)	($50M)	($126M)	($65M)	($67M)	($36M)	($57M)	($53M)	($41M)	($32M)	($14M)	($1M)
Earnings Per Share (EPS)	$-2.46	$-3.02	$-3.66	$-3.96	$-4.57	$-4.90	$-5.30	$-24.01	$-12.54	$-21.18	$-11.82	$-19.32	$-24.82	$-21.80	$-20.45	$-8.11	$-8.66
Shares Outstanding (M)	100M	69M	36M	22M	16M	15M	13M	6M	6M	3M	3M	3M	2M	2M	2M	2M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VSTM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$40M	$19M	$18M	$11M	$2M	$0M	($10M)	$0M
Gross Profit	$36M	$16M	$15M	$10M	$2M	$0M	($10M)	$0M
Gross Margin %	89.9%	83.7%	83.5%	85.1%	79.1%	—	100.1%	—
Operating Income (EBIT)	($33M)	($45M)	($41M)	($41M)	($44M)	($44M)	($32M)	($37M)
Operating Margin %	-81.6%	-240.5%	-236.5%	-362.2%	-2047.9%	—	316.7%	—
Net Income	($35M)	($37M)	($33M)	($99M)	($26M)	($52M)	($65M)	($24M)
Net Margin %	-86.5%	-196.0%	-187.7%	-876.3%	-1213.6%	—	647.1%	—
EBITDA	($33M)	($36M)	($32M)	($98M)	($26M)	($52M)	($63M)	($23M)
Earnings Per Share (EPS)	$-0.35	$-0.37	$-0.39	$-1.35	$-0.35	$-0.96	$-1.70	$-0.60
Shares Outstanding (M)	100M	99M	83M	73M	74M	54M	38M	40M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VSTM Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Cash from Operations (CFO)	($162M)	($138M)	($105M)	($86M)	($64M)	($54M)	($34M)	($139M)	($75M)	($57M)	($29M)	($46M)	($37M)	($26M)	($23M)	($10M)	$0M
Capital Expenditures (CapEx)	$1M	$10M	$0M	$0M	$0M	$0M	$0M	$0M	$24M	$2M	$0M	$0M	$2M	$0M	$0M	$1M	$0M
Free Cash Flow (FCF)	($164M)	($147M)	($105M)	($86M)	($64M)	($54M)	($34M)	($139M)	($98M)	($59M)	($30M)	($46M)	($39M)	($26M)	($23M)	($11M)	$0M
FCF Margin %	-186.8%	-475.9%	-1048.0%	—	-2452.7%	-2615.6%	-37.9%	-793.6%	-366.9%	—	—	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$0M	$0M	$0M	$0M	—	$0M	$0M	$0M	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VSTM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($44M)	($52M)	($30M)	($36M)	($33M)	($39M)	($25M)	($24M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($44M)	($52M)	($31M)	($36M)	($33M)	($39M)	($25M)	($24M)
FCF Margin %	-109.6%	-279.1%	-178.5%	-322.1%	-1528.5%	—	251.6%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VSTM Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31
Total Assets	$207M	$246M	$102M	$150M	$95M	$109M	$154M	$145M	$277M	$90M	$84M	$113M	$99M	$125M	$93M	$59M	$4M
Cash & Cash Equivalents	$136M	$205M	$89M	$78M	$75M	$21M	$68M	$44M	$130M	$82M	$32M	$25M	$34M	$19M	$10M	$21M	$4M
Total Liabilities	$157M	$189M	$130M	$92M	$48M	$21M	$39M	$138M	$153M	$32M	$11M	$11M	$10M	$8M	$2M	$72M	$0M
Total Debt (Short + Long-Term)	$83M	$82M	$42M	$41M	$26M	$1M	$20M	$104M	$120M	$30M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$50M	$57M	($29M)	$57M	$47M	$88M	$115M	$7M	$124M	$58M	$72M	$102M	$89M	$117M	$90M	$55M	$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VSTM viewer.

Other Companies in BIOTECHNOLOGY

VOR · Vor Biopharma Inc — $1 billion
MNKD · MannKind Corp — $1 billion
INBX · Inhibrx Biosciences, Inc. — $1 billion
AVLN · Avalyn Pharma Inc. Common Stock — $1 billion
SGP · SpyGlass Pharma, Inc. — $1 billion
JANX · Janux Therapeutics Inc — $1 billion
SPTX · Seaport Therapeutics, Inc. Common Stock — $1 billion
IMTX · Immatics NV — $1 billion

← VSTL All “V” companies VSTS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.